How do life sciences companies build an IT landscape that is GxP-compliant, validated and at the same time fast enough for the business?

In regulated environments, it is not the breadth of a system's functionality that decides project success, but the sequence of the checks. Three strands must come together before a system goes into production: validatability under GAMP 5, data integrity to ALCOA+ with a tamper-evident audit trail against 21 CFR Part 11 and the EU GMP Guide Annex 11, and supplier responsibility for outsourced records. Companies that examine these strands only after the selection decision lose the weakest one as a bottleneck, usually the validatability of a system that has already been purchased. That is precisely why the regulatory pre-assessment belongs at the start of the selection process and not at the end of the implementation.

The second lever is the data architecture across system boundaries. Every uncontrolled transfer between silos that have grown over time is a potential data integrity breach, which Annex 11 requires to be a controlled, traceable process. Once data-driven or AI-supported applications are added, the AI Act (EU) 2024/1689 adds a risk-based layer of obligations, and where there is a personal reference the GDPR (EU) 2016/679 applies in parallel. We therefore start early: first assess the GxP relevance and the risk of each application, then anchor validation, audit trail review and data protection so that the effort shifts to the front, where corrections are cheap, rather than into the inspection, where they delay the project.